APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilar Drug

Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

Selected research

Market Structure

Global Biosimilar Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025186 pages

Choose your research edition.

Industry ResearchBiosimilar Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilar Drug Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Biosimilar Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilar Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilar Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

In China, Biosimilar Drug key players include CP Guojian Pharma, Biotech Pharma, Celgen Pharma, etc. Global top three manufacturers hold a share over 70%.

Read the full market overview

East China is the largest market, with a share over 70%, followed by North China, with a share about 15 percent.

In terms of product, Tablets is the largest segment, with a share over 65%. And in terms of application, the largest application is Ankylosing Spondylitis, followed by Rheumatoid Arthrtis, Tumor, Cardiovascular, etc.

This report provides an overview of the global Biosimilar Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biosimilar Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biosimilar Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biosimilar Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Biosimilar Drug Segment by Company

CP Guojian Pharma

Biotech Pharma

Celgen Pharma

Henlius

Amgen

Eli Lilly

Sandoz

Changchun High Tech

Innovent

Biosimilar Drug Segment by Type

Injection

Tablets

Other Types

Biosimilar Drug Segment by Application

Ankylosing Spondylitis

Tumor

Rheumatoid Arthrtis

Cardiovascular

Other Application

Biosimilar Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biosimilar Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biosimilar Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Biosimilar Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Biosimilar Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Biosimilar Drug Industry Trends Table 2. Biosimilar Drug Industry Drivers Table 3. Biosimilar Drug Industry Opportunities and Challenges Table 4. Biosimilar Drug Industry Restraints Table 5. Global Biosimilar Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Biosimilar Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Biosimilar Drug Sales by Manufacturers (K Dose) & (2021-2026) Table 8. Global Biosimilar Drug Sales Market Share by Manufacturers Table 9. Global Biosimilar Drug Average Sales Price (USD/Dose) of Manufacturers (2021-2026) Table 10. Global Biosimilar Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Biosimilar Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Biosimilar Drug Manufacturers, Product Type & Application Table 13. Global Biosimilar Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Biosimilar Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Injection Table 17. Major Manufacturers of Tablets Table 18. Major Manufacturers of Other Types Table 19. Global Biosimilar Drug Sales by Type 2021 VS 2025 VS 2032 (K Dose) Table 20. Global Biosimilar Drug Sales by Type (2021-2026) & (K Dose) Table 21. Global Biosimilar Drug Sales by Type (2027-2032) & (K Dose) Table 22. Global Biosimilar Drug Sales Market Share by Type (2021-2026) Table 23. Global Biosimilar Drug Sales Market Share by Type (2027-2032) Table 24. Global Biosimilar Drug Revenue by Type 2021 VS 2025 VS 2032 (K Dose) Table 25. Global Biosimilar Drug Revenue by Type (2021-2026) & (K Dose) Table 26. Global Biosimilar Drug Revenue by Type (2027-2032) & (K Dose) Table 27. Global Biosimilar Drug Revenue Market Share by Type (2021-2026) Table 28. Global Biosimilar Drug Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Ankylosing Spondylitis Table 30. Major Manufacturers of Tumor Table 31. Major Manufacturers of Rheumatoid Arthrtis Table 32. Major Manufacturers of Cardiovascular Table 33. Major Manufacturers of Other Application Table 34. Global Biosimilar Drug Sales by Application 2021 VS 2025 VS 2032 (K Dose) Table 35. Global Biosimilar Drug Sales by Application (2021-2026) & (K Dose) Table 36. Global Biosimilar Drug Sales by Application (2027-2032) & (K Dose) Table 37. Global Biosimilar Drug Sales Market Share by Application (2021-2026) Table 38. Global Biosimilar Drug Sales Market Share by Application (2027-2032) Table 39. Global Biosimilar Drug Revenue by Application 2021 VS 2025 VS 2032 (K Dose) Table 40. Global Biosimilar Drug Revenue by Application (2021-2026) & (K Dose) Table 41. Global Biosimilar Drug Revenue by Application (2027-2032) & (K Dose) Table 42. Global Biosimilar Drug Revenue Market Share by Application (2021-2026) Table 43. Global Biosimilar Drug Revenue Market Share by Application (2027-2032) Table 44. Global Biosimilar Drug Sales by Region: 2021 VS 2025 VS 2032 (K Dose) Table 45. Global Biosimilar Drug Sales by Region (2021-2026) & (K Dose) Table 46. Global Biosimilar Drug Sales Market Share by Region (2021-2026) Table 47. Global Biosimilar Drug Sales Forecasted by Region (2027-2032) & (K Dose) Table 48. Global Biosimilar Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Biosimilar Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Dose) Table 50. North America Biosimilar Drug Sales by Country (2021-2026) & (K Dose) Table 51. North America Biosimilar Drug Sales by Country (2027-2032) & (K Dose) Table 52. Europe Biosimilar Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Dose) Table 53. Europe Biosimilar Drug Sales by Country (2021-2026) & (K Dose) Table 54. Europe Biosimilar Drug Sales by Country (2027-2032) & (K Dose) Table 55. Asia Pacific Biosimilar Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Dose) Table 56. Asia Pacific Biosimilar Drug Sales by Country (2021-2026) & (K Dose) Table 57. Asia Pacific Biosimilar Drug Sales by Country (2027-2032) & (K Dose) Table 58. South America, Middle East and Africa Biosimilar Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Dose) Table 59. South America, Middle East and Africa Biosimilar Drug Sales by Country (2021-2026) & (K Dose) Table 60. South America, Middle East and Africa Biosimilar Drug Sales by Country (2027-2032) & (K Dose) Table 61. Global Biosimilar Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Biosimilar Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Biosimilar Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Biosimilar Drug Revenue Market Share by Region (2021-2026) Table 65. Global Biosimilar Drug Revenue Market Share by Region (2027-2032) Table 66. CP Guojian Pharma Company Information Table 67. CP Guojian Pharma Business Overview Table 68. CP Guojian Pharma Biosimilar Drug Sales (K Dose), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. CP Guojian Pharma Biosimilar Drug Product Portfolio Table 70. CP Guojian Pharma Recent Development Table 71. Biotech Pharma Company Information Table 72. Biotech Pharma Business Overview Table 73. Biotech Pharma Biosimilar Drug Sales (K Dose), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Biotech Pharma Biosimilar Drug Product Portfolio Table 75. Biotech Pharma Recent Development Table 76. Celgen Pharma Company Information Table 77. Celgen Pharma Business Overview Table 78. Celgen Pharma Biosimilar Drug Sales (K Dose), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Celgen Pharma Biosimilar Drug Product Portfolio Table 80. Celgen Pharma Recent Development Table 81. Henlius Company Information Table 82. Henlius Business Overview Table 83. Henlius Biosimilar Drug Sales (K Dose), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Henlius Biosimilar Drug Product Portfolio Table 85. Henlius Recent Development Table 86. Amgen Company Information Table 87. Amgen Business Overview Table 88. Amgen Biosimilar Drug Sales (K Dose), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Amgen Biosimilar Drug Product Portfolio Table 90. Amgen Recent Development Table 91. Eli Lilly Company Information Table 92. Eli Lilly Business Overview Table 93. Eli Lilly Biosimilar Drug Sales (K Dose), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Eli Lilly Biosimilar Drug Product Portfolio Table 95. Eli Lilly Recent Development Table 96. Sandoz Company Information Table 97. Sandoz Business Overview Table 98. Sandoz Biosimilar Drug Sales (K Dose), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Sandoz Biosimilar Drug Product Portfolio Table 100. Sandoz Recent Development Table 101. Changchun High Tech Company Information Table 102. Changchun High Tech Business Overview Table 103. Changchun High Tech Biosimilar Drug Sales (K Dose), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Changchun High Tech Biosimilar Drug Product Portfolio Table 105. Changchun High Tech Recent Development Table 106. Innovent Company Information Table 107. Innovent Business Overview Table 108. Innovent Biosimilar Drug Sales (K Dose), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Innovent Biosimilar Drug Product Portfolio Table 110. Innovent Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Biosimilar Drug Distributors List Table 114. Biosimilar Drug Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Biosimilar Drug Product Image Figure 2. Global Biosimilar Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilar Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Biosimilar Drug Sales (2021-2032) & (K Dose) Figure 5. Global Biosimilar Drug Average Price (USD/Dose) & (2021-2032) Figure 6. Global Top 5 and 10 Biosimilar Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Injection Image Figure 9. Tablets Image Figure 10. Other Types Image Figure 11. Global Biosimilar Drug Sales by Type (2021 VS 2025 VS 2032) & (K Dose) Figure 12. Global Biosimilar Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Biosimilar Drug Sales Market Share by Type (2021-2032) Figure 14. Global Biosimilar Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Dose) Figure 15. Global Biosimilar Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Biosimilar Drug Revenue Market Share by Type (2021-2032) Figure 17. Ankylosing Spondylitis Image Figure 18. Tumor Image Figure 19. Rheumatoid Arthrtis Image Figure 20. Cardiovascular Image Figure 21. Other Application Image Figure 22. Global Biosimilar Drug Sales by Application (2021 VS 2025 VS 2032) & (K Dose) Figure 23. Global Biosimilar Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Biosimilar Drug Sales Market Share by Application (2021-2032) Figure 25. Global Biosimilar Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Dose) Figure 26. Global Biosimilar Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Biosimilar Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 29. North America Biosimilar Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 31. Canada Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 32. Mexico Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 33. Europe Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 34. Europe Biosimilar Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 36. France Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 37. U.K. Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 38. Italy Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 39. Netherlands Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 40. Asia Pacific Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 41. Asia Pacific Biosimilar Drug Sales Market Share by Country (2021-2032) Figure 42. China Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 43. Japan Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 44. South Korea Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 45. Southeast Asia Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 46. India Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 47. Australia Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 48. South America, Middle East and Africa Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 49. South America, Middle East and Africa Biosimilar Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 51. South Africa Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 52. Saudi Arabia Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 53. Turkey Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 54. Argentina Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 55. UAE Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 56. Egypt Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 57. Chile Biosimilar Drug Sales and Growth Rate (2021-2032) & (K Dose) Figure 58. Global Biosimilar Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Biosimilar Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Biosimilar Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Biosimilar Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Biosimilar Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Biosimilar Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Biosimilar Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Biosimilar Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Biosimilar Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Biosimilar Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Biosimilar Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Biosimilar Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Tablets
  • Other Types
Applications
  • Ankylosing Spondylitis
  • Tumor
  • Rheumatoid Arthrtis
  • Cardiovascular
  • Other Application
Companies covered
  • CP Guojian Pharma
  • Biotech Pharma
  • Celgen Pharma
  • Henlius
  • Amgen
  • Eli Lilly
  • Sandoz
  • Changchun High Tech
  • Innovent

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biosimilar Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biosimilar Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Biosimilar Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Biosimilar Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Biosimilar Drug Market Dynamics
  1. 2.1 Biosimilar Drug Industry Trends
  2. 2.2 Biosimilar Drug Industry Drivers
  3. 2.3 Biosimilar Drug Industry Opportunities and Challenges
  4. 2.4 Biosimilar Drug Industry Restraints
3 Biosimilar Drug Market by Manufacturers
  1. 3.1 Global Biosimilar Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Biosimilar Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Biosimilar Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Biosimilar Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biosimilar Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Biosimilar Drug Manufacturers, Product Type & Application
  7. 3.7 Global Biosimilar Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biosimilar Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biosimilar Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biosimilar Drug Tier 1, Tier 2, and Tier 3
4 Biosimilar Drug Market by Type
  1. 4.1 Biosimilar Drug Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 Tablets
  4. 4.1.3 Other Types
  5. 4.2 Global Biosimilar Drug Sales by Type
  6. 4.2.1 Global Biosimilar Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Biosimilar Drug Sales by Type (2021-2032)
  8. 4.2.3 Global Biosimilar Drug Sales Market Share by Type (2021-2032)
  9. 4.3 Global Biosimilar Drug Revenue by Type
  10. 4.3.1 Global Biosimilar Drug Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Biosimilar Drug Revenue by Type (2021-2032)
  12. 4.3.3 Global Biosimilar Drug Revenue Market Share by Type (2021-2032)
5 Biosimilar Drug Market by Application
  1. 5.1 Biosimilar Drug Application Introduction
  2. 5.1.1 Ankylosing Spondylitis
  3. 5.1.2 Tumor
  4. 5.1.3 Rheumatoid Arthrtis
  5. 5.1.4 Cardiovascular
  6. 5.1.5 Other Application
  7. 5.2 Global Biosimilar Drug Sales by Application
  8. 5.2.1 Global Biosimilar Drug Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Biosimilar Drug Sales by Application (2021-2032)
  10. 5.2.3 Global Biosimilar Drug Sales Market Share by Application (2021-2032)
  11. 5.3 Global Biosimilar Drug Revenue by Application
  12. 5.3.1 Global Biosimilar Drug Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Biosimilar Drug Revenue by Application (2021-2032)
  14. 5.3.3 Global Biosimilar Drug Revenue Market Share by Application (2021-2032)
6 Global Biosimilar Drug Sales by Region
  1. 6.1 Global Biosimilar Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biosimilar Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Biosimilar Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Biosimilar Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biosimilar Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Biosimilar Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Biosimilar Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Biosimilar Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Biosimilar Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Biosimilar Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Biosimilar Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Biosimilar Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Biosimilar Drug Revenue by Region
  1. 7.1 Global Biosimilar Drug Revenue by Region
  2. 7.1.1 Global Biosimilar Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Biosimilar Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Biosimilar Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Biosimilar Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Biosimilar Drug Revenue (2021-2032)
  8. 7.2.2 North America Biosimilar Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Biosimilar Drug Revenue (2021-2032)
  11. 7.3.2 Europe Biosimilar Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Biosimilar Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Biosimilar Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Biosimilar Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Biosimilar Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CP Guojian Pharma
  2. 8.1.1 CP Guojian Pharma Company Information
  3. 8.1.2 CP Guojian Pharma Business Overview
  4. 8.1.3 CP Guojian Pharma Biosimilar Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CP Guojian Pharma Biosimilar Drug Product Portfolio
  6. 8.1.5 CP Guojian Pharma Recent Developments
  7. 8.2 Biotech Pharma
  8. 8.2.1 Biotech Pharma Company Information
  9. 8.2.2 Biotech Pharma Business Overview
  10. 8.2.3 Biotech Pharma Biosimilar Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Biotech Pharma Biosimilar Drug Product Portfolio
  12. 8.2.5 Biotech Pharma Recent Developments
  13. 8.3 Celgen Pharma
  14. 8.3.1 Celgen Pharma Company Information
  15. 8.3.2 Celgen Pharma Business Overview
  16. 8.3.3 Celgen Pharma Biosimilar Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Celgen Pharma Biosimilar Drug Product Portfolio
  18. 8.3.5 Celgen Pharma Recent Developments
  19. 8.4 Henlius
  20. 8.4.1 Henlius Company Information
  21. 8.4.2 Henlius Business Overview
  22. 8.4.3 Henlius Biosimilar Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Henlius Biosimilar Drug Product Portfolio
  24. 8.4.5 Henlius Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen Biosimilar Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Amgen Biosimilar Drug Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly Biosimilar Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly Biosimilar Drug Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Sandoz
  38. 8.7.1 Sandoz Company Information
  39. 8.7.2 Sandoz Business Overview
  40. 8.7.3 Sandoz Biosimilar Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sandoz Biosimilar Drug Product Portfolio
  42. 8.7.5 Sandoz Recent Developments
  43. 8.8 Changchun High Tech
  44. 8.8.1 Changchun High Tech Company Information
  45. 8.8.2 Changchun High Tech Business Overview
  46. 8.8.3 Changchun High Tech Biosimilar Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Changchun High Tech Biosimilar Drug Product Portfolio
  48. 8.8.5 Changchun High Tech Recent Developments
  49. 8.9 Innovent
  50. 8.9.1 Innovent Company Information
  51. 8.9.2 Innovent Business Overview
  52. 8.9.3 Innovent Biosimilar Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Innovent Biosimilar Drug Product Portfolio
  54. 8.9.5 Innovent Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biosimilar Drug Value Chain Analysis
  2. 9.1.1 Biosimilar Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biosimilar Drug Production Mode & Process
  6. 9.2 Biosimilar Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biosimilar Drug Distributors
  9. 9.2.3 Biosimilar Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst